MX2017007138A - Metodos y composiciones para terapia celular adoptiva. - Google Patents
Metodos y composiciones para terapia celular adoptiva.Info
- Publication number
- MX2017007138A MX2017007138A MX2017007138A MX2017007138A MX2017007138A MX 2017007138 A MX2017007138 A MX 2017007138A MX 2017007138 A MX2017007138 A MX 2017007138A MX 2017007138 A MX2017007138 A MX 2017007138A MX 2017007138 A MX2017007138 A MX 2017007138A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor
- methods
- cells
- prior
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan métodos para múltiples administraciones de células para terapia celular adoptiva, y para administrar células a sujetos que han recibido administraciones previas, y composiciones y artículos de fabricación para el use en los métodos. Las células generalmente expresan moléculas recombinantes tales como receptores recombinantes, par ejemplo receptores de antígeno quimérico (CARS) y/u otros receptores transgénicos. Los métodos pueden involucrar la administración de células que expresan un primer o previo receptor(es) y células que expresan un segundo o subsecuente receptor(es), el segundo o subsecuente receptor(es) que es distinto del primero, y que generalmente no expresa el primer receptor y/o la administración de las células que expresan el segundo receptor a un sujeto que ha recibido la primera administración. Los métodos pueden proporcionar varias ventajas, tales como eficacia mejorada en el contexto de una respuesta inmune en el sujeto contra el primero o previo receptor y/o en el contexto de perdida de antígeno, regulación hacia abajo o modificación, después de una primera o previa administración.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462087224P | 2014-12-03 | 2014-12-03 | |
PCT/US2015/063839 WO2016090190A1 (en) | 2014-12-03 | 2015-12-03 | Methods and compositions for adoptive cell therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017007138A true MX2017007138A (es) | 2017-08-28 |
Family
ID=55022703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017007138A MX2017007138A (es) | 2014-12-03 | 2015-12-03 | Metodos y composiciones para terapia celular adoptiva. |
MX2022005955A MX2022005955A (es) | 2014-12-03 | 2017-06-05 | Metodos y composiciones para terapia celular adoptiva. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005955A MX2022005955A (es) | 2014-12-03 | 2017-06-05 | Metodos y composiciones para terapia celular adoptiva. |
Country Status (11)
Country | Link |
---|---|
US (3) | US11266739B2 (es) |
EP (2) | EP3766895A1 (es) |
JP (2) | JP7068820B2 (es) |
KR (1) | KR20170087514A (es) |
CN (1) | CN107206025A (es) |
AU (2) | AU2015358400B2 (es) |
CA (1) | CA2969456A1 (es) |
ES (1) | ES2819553T3 (es) |
HK (1) | HK1244826A1 (es) |
MX (2) | MX2017007138A (es) |
WO (1) | WO2016090190A1 (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101605421B1 (ko) | 2014-03-05 | 2016-03-23 | 국립암센터 | B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도 |
JP7057669B2 (ja) | 2014-10-20 | 2022-04-20 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法において投薬するための方法および組成物 |
EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
RU2021134624A (ru) | 2015-10-22 | 2022-03-15 | Джуно Терапьютикс Гмбх | Способы, наборы, средства и устройства для трансдукции |
JP7184645B2 (ja) * | 2015-12-03 | 2022-12-06 | ジュノー セラピューティクス インコーポレイテッド | 修飾キメラ受容体ならびに関連する組成物および方法 |
US20180135011A1 (en) * | 2017-03-13 | 2018-05-17 | Berkeley Lights, Inc. | Selection and cloning of t lymphocytes in a microfluidic device |
CN109715668A (zh) | 2016-08-02 | 2019-05-03 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重编程的组合物和方法 |
EP3504550B1 (en) * | 2016-08-26 | 2021-07-21 | Juno Therapeutics, Inc. | Methods of enumerating particles present in a cell composition |
CN110087657A (zh) | 2016-09-28 | 2019-08-02 | 阿托莎遗传股份有限公司 | 过继细胞治疗的方法 |
CA3039014A1 (en) * | 2016-10-04 | 2018-04-12 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
PT3445787T (pt) | 2016-10-07 | 2021-03-15 | Tcr2 Therapeutics Inc | Composições e métodos para reprogramação de recetores de célula t com o uso de proteínas de fusão |
CN110177803A (zh) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
CN110249046A (zh) * | 2016-12-05 | 2019-09-17 | 朱诺治疗学股份有限公司 | 用于过继细胞疗法的工程化细胞的产生 |
CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技(香港)有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
WO2018154386A1 (en) * | 2017-02-21 | 2018-08-30 | Eutilex Co., Ltd. | Hla-dr car-t compositions and methods of making and using the same |
IL292352B2 (en) | 2017-03-14 | 2024-03-01 | Juno Therapeutics Inc | Methods of freezing |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
CN110573177A (zh) * | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
KR20200015580A (ko) | 2017-06-07 | 2020-02-12 | 시애틀 지네틱스, 인크. | 감소된 표면 푸코실화를 갖는 t 세포 및 이를 생산하고 사용하는 방법 |
IL270990B2 (en) * | 2017-06-07 | 2024-02-01 | Precigen Inc | Expression of new cell markers |
JP2020526194A (ja) * | 2017-06-29 | 2020-08-31 | ジュノー セラピューティクス インコーポレイテッド | 免疫療法薬と関連する毒性を評価するためのマウスモデル |
SG11202005272SA (en) * | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
CN109988242A (zh) * | 2018-01-02 | 2019-07-09 | 武汉波睿达生物科技有限公司 | 联合嵌合抗原受体、表达载体、慢病毒及t细胞 |
AU2019222644B2 (en) | 2018-02-13 | 2021-04-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
KR20200140867A (ko) | 2018-04-06 | 2020-12-16 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3'-사이클릭 다이뉴클레오티드 |
US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’-環二核苷酸 |
MX2020012137A (es) | 2018-05-14 | 2021-01-29 | Gilead Sciences Inc | Inhibidores de mcl-1. |
JP7105359B2 (ja) | 2018-07-13 | 2022-07-22 | ギリアード サイエンシーズ, インコーポレイテッド | Pd-1/pd-l1阻害剤 |
EP3835320A4 (en) | 2018-08-10 | 2022-06-01 | Eutilex Co., Ltd. | BINDING OF CHEMERA ANTIGEN RECEPTOR TO HLA-DR, AND CAR-T CELL |
US20220348682A1 (en) | 2018-08-30 | 2022-11-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
MX2021015452A (es) | 2019-06-25 | 2022-02-11 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso. |
JP7371243B2 (ja) | 2019-10-18 | 2023-10-30 | フォーティ セブン, インコーポレイテッド | 骨髄異形成症候群及び急性骨髄性白血病を治療するための併用療法 |
CN114599392A (zh) | 2019-10-31 | 2022-06-07 | 四十七公司 | 基于抗cd47和抗cd20的血癌治疗 |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
EP4104840A4 (en) * | 2020-02-13 | 2023-08-23 | Beijing Immunochina Pharmaceuticals Co., Ltd. | OPTIMIZATION OF A CHEMERA ANTIGEN RECEPTOR |
AU2021264550A1 (en) | 2020-05-01 | 2022-11-17 | Gilead Sciences, Inc. | CD73 inhibiting 2,4-dioxopyrimidine compounds |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023154890A2 (en) * | 2022-02-11 | 2023-08-17 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding steap1 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (es) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
CA2096222C (en) | 1990-11-13 | 1998-12-29 | Stephen D. Lupton | Bifunctional selectable fusion genes |
EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
CA2410510A1 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
ATE468348T1 (de) | 2001-09-26 | 2010-06-15 | Government Of The Us Secretary | Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
WO2008121420A1 (en) | 2007-03-30 | 2008-10-09 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
ES2640216T3 (es) | 2007-12-07 | 2017-11-02 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
US8591889B2 (en) | 2008-04-04 | 2013-11-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies specific for CD22 |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
ES2961498T3 (es) | 2008-08-26 | 2024-03-12 | Hope City | Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T |
KR20110122859A (ko) | 2009-02-23 | 2011-11-11 | 그렌마크 파머수티칼스 에스. 아. | Cd19에 결합하는 인간화된 항체 및 그것의 용도 |
US20120128586A1 (en) * | 2009-06-24 | 2012-05-24 | The Feinstein Institute For Medical Research | Method for treating chronic lymphocytic leukemia |
JP5956342B2 (ja) | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープCity of Hope | 形質導入T細胞選択のためのトランケート上皮増殖因子レセプタ(EGFRt) |
JP5712516B2 (ja) * | 2010-07-14 | 2015-05-07 | 住友電気工業株式会社 | 半導体装置 |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
ES2841983T3 (es) | 2011-03-23 | 2021-07-12 | Hutchinson Fred Cancer Res | Método y composiciones para inmunoterapia celular |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
US9366138B2 (en) * | 2011-07-28 | 2016-06-14 | Pratt & Whitney Canada Corp. | Rotary internal combustion engine with phasing gear |
AU2012325915A1 (en) | 2011-10-20 | 2014-04-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
BR112014011417B1 (pt) | 2011-11-11 | 2021-10-13 | Fred Hutchinson Cancer Research Center | Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1 |
EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
KR20150009556A (ko) | 2012-05-03 | 2015-01-26 | 프레드 헛친슨 켄서 리서치 센터 | 증강된 친화성 t 세포 수용체 및 이의 제조 방법 |
BR112015000638A2 (pt) | 2012-07-13 | 2017-08-08 | Univ Pennsylvania | sequência de ácido nucleico isolada, célula, métodos para estimular uma resposta imune mediada pela célula t e uma população de célula alvo ou tecido em um mamífero, para provimento de imunidade antitumor em um mamífero, para tratamento de um mamífero que tenha uma doença, distúrbio ou condição associado com uma expressão elevada de um antígeno de tumor |
WO2014031687A1 (en) | 2012-08-20 | 2014-02-27 | Jensen, Michael | Method and compositions for cellular immunotherapy |
CN112430580A (zh) | 2012-10-02 | 2021-03-02 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
JP6338252B2 (ja) | 2012-10-24 | 2018-06-06 | アメリカ合衆国 | M971キメラ抗原受容体 |
CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
NZ712693A (en) | 2013-03-15 | 2021-07-30 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
US10144770B2 (en) | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
EP3593812A3 (en) | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
JP6788573B6 (ja) | 2014-04-10 | 2020-12-16 | シアトル チルドレンズ ホスピタル, ディービーエー シアトル チルドレンズ リサーチ インスティテュート | メトトレキサートによる選択と組み合わせたSleeping Beautyトランスポゾンによる遺伝子改変T細胞の製造 |
SG11201700770PA (en) * | 2014-08-19 | 2017-03-30 | Novartis Ag | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment |
JP7057669B2 (ja) | 2014-10-20 | 2022-04-20 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法において投薬するための方法および組成物 |
CN104910279B (zh) | 2015-06-05 | 2019-02-22 | 重庆精准生物技术有限公司 | 靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用 |
JP7184645B2 (ja) | 2015-12-03 | 2022-12-06 | ジュノー セラピューティクス インコーポレイテッド | 修飾キメラ受容体ならびに関連する組成物および方法 |
WO2017096327A2 (en) | 2015-12-03 | 2017-06-08 | Juno Therapeutics, Inc. | Compositions and methods for reducing immune responses against cell therapies |
-
2015
- 2015-12-03 JP JP2017529321A patent/JP7068820B2/ja active Active
- 2015-12-03 US US14/958,919 patent/US11266739B2/en active Active
- 2015-12-03 KR KR1020177018369A patent/KR20170087514A/ko not_active Application Discontinuation
- 2015-12-03 MX MX2017007138A patent/MX2017007138A/es unknown
- 2015-12-03 CN CN201580075303.2A patent/CN107206025A/zh active Pending
- 2015-12-03 AU AU2015358400A patent/AU2015358400B2/en active Active
- 2015-12-03 ES ES15816318T patent/ES2819553T3/es active Active
- 2015-12-03 WO PCT/US2015/063839 patent/WO2016090190A1/en active Application Filing
- 2015-12-03 CA CA2969456A patent/CA2969456A1/en active Pending
- 2015-12-03 EP EP20180622.1A patent/EP3766895A1/en active Pending
- 2015-12-03 EP EP15816318.8A patent/EP3227323B1/en active Active
-
2017
- 2017-06-05 MX MX2022005955A patent/MX2022005955A/es unknown
-
2018
- 2018-03-27 HK HK18104179.5A patent/HK1244826A1/zh unknown
-
2020
- 2020-12-04 AU AU2020281158A patent/AU2020281158B2/en active Active
-
2022
- 2022-01-28 US US17/588,149 patent/US20220280642A1/en active Pending
- 2022-04-20 JP JP2022069168A patent/JP2022101625A/ja active Pending
-
2023
- 2023-10-20 US US18/491,633 patent/US20240066122A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2015358400A1 (en) | 2017-06-22 |
KR20170087514A (ko) | 2017-07-28 |
MX2022005955A (es) | 2022-06-29 |
AU2020281158A1 (en) | 2021-01-14 |
AU2015358400B2 (en) | 2020-09-10 |
CN107206025A (zh) | 2017-09-26 |
CA2969456A1 (en) | 2016-06-09 |
EP3227323B1 (en) | 2020-08-05 |
ES2819553T3 (es) | 2021-04-16 |
AU2020281158B2 (en) | 2024-02-08 |
EP3227323A1 (en) | 2017-10-11 |
US20220280642A1 (en) | 2022-09-08 |
WO2016090190A1 (en) | 2016-06-09 |
JP2017537919A (ja) | 2017-12-21 |
EP3766895A1 (en) | 2021-01-20 |
US20240066122A1 (en) | 2024-02-29 |
US11266739B2 (en) | 2022-03-08 |
JP7068820B2 (ja) | 2022-05-17 |
JP2022101625A (ja) | 2022-07-06 |
HK1244826A1 (zh) | 2018-08-17 |
US20160158359A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005955A (es) | Metodos y composiciones para terapia celular adoptiva. | |
EP4219689A3 (en) | Immune effector cell therapies with enhanced efficacy | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
MX2017000646A (es) | Celulas geneticamente modificadas para terapia celular adoptiva. | |
NZ725201A (en) | Improved methods for manufacturing adoptive cell therapies | |
MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
MX2022012082A (es) | Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva. | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
AU2017240801A8 (en) | Chimeric receptors to FLT3 and methods of use thereof | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
MX2019014008A (es) | Composiciones y usos para inmunoterapia. | |
MY195089A (en) | Anti-Tim-3 Antibodies and Methods of use thereof | |
WO2016090034A3 (en) | Methods for b cell preconditioning in car therapy | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
AU2016335217A8 (en) | Antigen receptors and uses thereof | |
PH12017500018A1 (en) | Myo-inositol and probiotics, and their use | |
NZ770578A (en) | Methods and compositions for adoptive cell therapy | |
AR101592A1 (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cd123 |